8-K: Nutex Health Reports Strong H1 2025 Revenue Growth

Nutex Health Inc. announced significant revenue and Adjusted EBITDA growth for the first half of 2025, alongside a new $25 million stock repurchase program.

Summary

• Total revenue for the first half of 2025 reached $455.8 million, marking a 217.5% increase from $143.5 million in the first half of 2024.
• Net income attributable to Nutex Health Inc. for the first half of 2025 was $3.5 million, a substantial improvement from a net loss of $0.7 million in the first half of 2024.
• Diluted income per share for the first half of 2025 was $0.55, compared to a loss per share of $0.15 for the same period in 2024.
• EBITDA for the first half of 2025 was $51.1 million, an increase of 227.4% from $15.6 million in the first half of 2024.
• Adjusted EBITDA for the first half of 2025 surged to $144.4 million, representing a 2144.2% increase from $6.4 million in the first half of 2024.
• Net cash from operating activities for the first half of 2025 was $78.2 million.
• For the three months ended June 30, 2025, total revenue increased by 220.7% to $244.0 million from $76.1 million in the same period of 2024.
• Net loss attributable to Nutex Health Inc. for the three months ended June 30, 2025, was $17.7 million, compared to a net loss of $0.4 million in the same period of 2024, primarily due to $78.7 million in non-cash stock-based compensation expense.
• EBITDA for the three months ended June 30, 2025, was $(0.5) million, a decrease of 105.4% from $8.5 million in the same period of 2024.
• Adjusted EBITDA for the three months ended June 30, 2025, was $71.6 million, up from $6.8 million in the same period of 2024.
• Total visits at the Hospital Division increased by 15.5% to 93,842 for the first half of 2025 and by 10.6% to 45,573 for the three months ended June 30, 2025.
• The Board of Directors authorized a stock repurchase program of up to $25.0 million of the company's common stock on August 14, 2025.
• As of June 30, 2025, the company reported total assets of $841.0 million, including cash and cash equivalents of $96.7 million, and long-term debt, net of $20.5 million.

Sentiment

Score: 8

Explanation: The company reported exceptional revenue and Adjusted EBITDA growth for the first half of 2025, a significant turnaround to net income, and strong operating cash flow. The authorized stock repurchase program signals management's confidence in the company's valuation and commitment to shareholder returns. While Q2 showed a net loss, it was primarily driven by non-cash stock-based compensation related to growth initiatives, which is a temporary factor.

Positives

• Total revenue for the first half of 2025 increased by 217.5% to $455.8 million, demonstrating strong top-line growth.
• Net income attributable to Nutex Health Inc. for the first half of 2025 was $3.5 million, a significant turnaround from a net loss of $0.7 million in the prior year period.
• Diluted income per share for the first half of 2025 was $0.55, reversing a loss per share of $0.15 in the first half of 2024.
• EBITDA for the first half of 2025 increased by 227.4% to $51.1 million, indicating improved operational profitability.
• Adjusted EBITDA for the first half of 2025 surged by 2144.2% to $144.4 million, highlighting strong underlying performance excluding certain non-cash items.
• Net cash from operating activities for the first half of 2025 was $78.2 million, reflecting robust cash generation from core operations.
• Operating income for the first half of 2025 improved by $107.6 million year over year to $114.3 million.
• Total visits at the Hospital Division increased by 15.5% for the first half of 2025 and 10.6% for the second quarter of 2025, indicating growing patient volumes.
• The Board of Directors authorized a $25.0 million stock repurchase program, signaling management's confidence in the company's valuation and commitment to enhancing shareholder value.
• The company achieved a record high cash balance of $96.7 million as of June 30, 2025, indicating strong liquidity.

Negatives

• Net loss attributable to Nutex Health Inc. for the second quarter of 2025 was $17.7 million, a significant increase from a net loss of $0.4 million in the same period of 2024.
• EBITDA attributable to Nutex Health for the second quarter of 2025 decreased by 105.4% to $(0.5) million, compared to $8.5 million for the same period in 2024.
• Total stock-based compensation expense was $78.7 million for the second quarter of 2025 and $106.4 million for the first half of 2025, which significantly impacted net income/loss, although approximately 99% is attributed to one-time obligations for under-construction and ramping hospitals.

Risks

• Ability to successfully execute the growth strategy.
• Changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act.
• Economic conditions.
• Dependence on management.
• Dilution to stockholders.
• Lack of capital.
• The effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services.
• Newly developing technologies.
• The company's ability to compete.
• Conflicts of interest in related party transactions.
• Regulatory matters.
• Protection of technology.
• Lack of industry standards.
• The effects of competition.
• The ability of the company to obtain future financing.

Future Outlook

The company anticipates executing its $25.0 million stock repurchase program opportunistically over the next several months with the goal of driving increased earnings per share and total shareholder return. Management also expects continued financial strength and solid fundamentals as it executes its growth plan for 2025.

Management Comments

• "We are pleased to report 217.5% revenue growth, Adjusted EBITDA attributable to Nutex Health of $144.4 million, a 643.5% increase in gross profit and a record high cash balance of $96.7 million, highlighting the company's continued financial strength and solid fundamentals as we execute on our growth plan for 2025." Jon Bates, Chief Financial Officer.
• "The arbitration process that we started in 2024 is now an ongoing part of our revenue cycle management process." Tom Vo, M.D., MBA, Chairman and Chief Executive Officer.
• "The Company believes its shares are currently undervalued, and our share repurchase program underscores our confidence in the long-term prospects of Nutex Health." Tom Vo, M.D., MBA, Chairman and Chief Executive Officer.
• "We anticipate executing this program opportunistically over the next several months with the goal of driving increased earnings per share and total shareholder return." Tom Vo, M.D., MBA, Chairman and Chief Executive Officer.

Industry Context

Nutex Health operates in the integrated healthcare delivery system, focusing on physician-led micro-hospitals, hospital outpatient departments (HOPDs), and primary care-centric, risk-bearing physician networks. The reported significant revenue and Adjusted EBITDA growth suggest successful expansion and increasing demand for its specialized healthcare models, potentially indicating strong performance within the evolving healthcare landscape that favors localized, efficient, and value-based care delivery.

Stakeholder Impact

• Shareholders: Potential positive impact from increased earnings per share due to the stock repurchase program and overall strong financial performance, which may lead to increased share value.
• Employees: Implied positive impact from company growth and expansion, with significant stock-based compensation being a notable factor.
• Customers (Patients): Continued expansion of micro-hospitals and HOPDs suggests increased access to healthcare services and potentially improved patient care models.

Next Steps

• Execution of the $25.0 million stock repurchase program over the next six months, to be performed opportunistically.
• Continued execution of the growth plan for 2025.
• Ongoing arbitration process as part of revenue cycle management.

Key Dates

Recommendation

The company demonstrated exceptional financial performance in the first half of 2025, with triple-digit revenue growth, a significant shift to net income, and a massive increase in Adjusted EBITDA. Operating cash flow is robust, and the balance sheet shows a strong cash position. The authorized $25 million stock repurchase program, explicitly aimed at increasing shareholder value and offsetting dilution, signals strong management confidence and a belief that the shares are undervalued. Despite a Q2 net loss, it was largely due to non-cash stock compensation tied to growth, which is a temporary factor. The underlying operational growth and profitability metrics are very compelling, suggesting strong future prospects and a favorable investment opportunity.

Keywords

Healthcare, Micro-hospitals, Hospital Outpatient Departments, Population Health Management, Physician Networks, Stock Repurchase, Financial Results, Revenue Growth, EBITDA, Adjusted EBITDA, NASDAQ: NUTX, Q2 2025, H1 2025